INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a common and preventable chronic disease with considerable health related and economic consequences (1) (2) (3) . COPD is one of the leading causes of morbidity and mortality in the world (4, 5) . The prevalence of COPD is continually rising and by 2020 COPD is predicted to be the third leading cause of death in the worldwide (4, 6) . It is the third major cause of death in the United States and 70% of the 24 million patients with COPD are < 65 (7). Mathers et al. reported that by 2030 COPD will be the fifth and tenth leading causes of disability adjusted life years (DALY) in middle-income and high-income countries, respectively (8) . A study reported that the prevalence of COPD in Iran and some other countries was approximately the same (9) . COPD death rate and DALY in Iran were estimated to be 26.3 and 395/100,000, respectively, which were nearly 5.9-, and 3.2 times higher than those in Japan (10) .
Chronic obstructive pulmonary disease has a major effect on healthcare costs, particularly direct medical costs (11) . Most studies of costs associated with COPD have shown significant associations between disease severity and economic burden of COPD exacerbation and diseases severity (3) . In 2010, COPD was responsible for $49.9 billion in direct and indirect costs in the United States (12) .
A study from the United States showed that the total cost of hospitalized patients with COPD was approximately $6,000.00 higher than that of hospitalized patients without COPD (13) . A study from Iran reported that the mean duration of hospital stay, which was the main driver of direct cost, was 11.82 days for patients with COPD exacerbation (14) . Hilleman et al. showed that the cost of hospital stay accounted for 40.4% and 62.6% of total costs for patients with mild and severe COPD, respectively (15) .
Another study showed that hospitalization costs represented 70% of all COPD-related medical care costs (16) . Predicting the cost of caring for patients with common chronic diseases is important for prioritizing health care utilization and policy making (17) . Very few studies have estimated the costs associated with COPD in Iran. The aim of this study was to analyze factors influencing costs of caring for patients hospitalized with acute exacerbation of COPD.
MATERIALS AND METHODS

Patients and study setting
The study sample consisted of 165 patients with diagnosis of COPD who were admitted to a referral public observed value of the dependent variable (y) and the predicted value (ŷ), were normally distributed. Therefore, we used multivariate regression analysis to determine predictors of hospitalization costs and LOS over nine days (corresponding to > 75th percentile) (18, 19) . The multivariate analysis initially included variables from the univariate analysis with P < 0.05. Stepwise approach was used to model independents variables. We considered P < 0.05 as statistically significant. We used SPSS version 20 (IBM Corporation, Armonk, NY, USA) for data analysis.
Given the retrospective nature of our study, informed consent was not required.
RESULTS
We reviewed the records of 165 patients, 72.7% of which were men. Mean (SD) age of the patients was 68.6 ± 12 years and 65.5% of them were ≥ 65 years old.
Furthermore, 91.5% of the patients lived in urban areas.
The patients were covered by medical insurance funds including social security (41.8%), Iranian Health insurance (10.9%), armed forces Insurance (2.4%) and rural insurance (23%). About 12.1% of the patients were uninsured and more than half of the patients (58.2%) were active smokers.
The most frequently present comorbidity in our study population was hypertension, which was present in 40.6% of patients. Twenty eight percent of the patients had diabetes mellitus, 15.2% suffered from orthopnea, and 11.5% of the patients suffered from asthma. Furthermore, our results showed a significant relationship between hospital costs per patient and past medical history of hypertension (P=0.017) and family history of COPD (P=0.036). The mean cost per patient was US $1,422.5 for patients with hypertension, compared to US $627.4 for those without it. The cost per patient for patients with a family history of COPD was 1.3 times higher than that for patients without a family history of COPD (US $1,253 vs. US $932.8). The mean hospital cost per patient for patients over 65 years of age was 1.3 times higher compared to that for younger patients (Table 1) . Also, according to 2. Optimizing hospital resources utilization can lead to reduced costs for patients and healthcare systems.
